Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 5:25 PM
Ignite Modification Date: 2025-12-24 @ 5:25 PM
NCT ID: NCT05480150
Eligibility Criteria: Inclusion Criteria: 1. Both biological parents are Han nationality; 2. Aged 16-65; 3. The subjects met the clinical diagnostic criteria of DSM-5 for depressive episodes of MDD/BD; 4. Did not take any immunomodulatory preparations within 1 month before enrollment; 5. No clear history of respiratory tract, urinary system, digestive system infection within 1 month before enrollment; Exclusion Criteria: 1. Those with schizophrenia spectrum, neurodevelopmental disorder, dementia, memory impairment or other cognitive impairment that meet the DIAGNOSTIC criteria of DSM-5; 2. Mental disorders caused by substance abuse (alcohol, drugs, etc.), patients suffering from serious physical diseases and immune system diseases, such as diabetes, thyroid diseases, hypertension, heart disease, liver and kidney dysfunction, autoimmune diseases, etc.; 3. Had received medication (such as antidepressants, antipsychotics, mood stabilizers, etc.) within 1 month before enrollment; 4. those who had used ECT before enrollment; 5. Currently have serious suicidal thoughts or behaviors, or serious excitement; 6. those who cannot follow the doctor's advice or have no guardian; 7. pregnant or breast-feeding women, or those who plan to become pregnant; 8. Contraindications to MRI examination; 9. Other conditions that the researcher considers inappropriate for inclusion.
Healthy Volunteers: True
Sex: ALL
Minimum Age: 16 Years
Maximum Age: 65 Years
Study: NCT05480150
Study Brief:
Protocol Section: NCT05480150